Trial Profile

A proof-of-concept Phase 2 study of eblasakimab in patients with COPD

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eblasakimab (Primary)
Indications Chronic obstructive pulmonary disease
Focus Proof of concept; Therapeutic Use

Most Recent Events

11 Mar 2024 New trial record
06 Mar 2024 According to an ASLAN Pharmaceuticals media release, company look forward to working with Dr.Krishnan and Dr.Panettieri, to consider potential proof-of-concept Phase 2 study designs in COPD and exploring novel endpoints from recently conducted biologic studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com